Studies showed that in patients with therapy-related AML or secondary AML, the analysis of the material from antecedent hematological disorder displayed mutations in TP53 which manifests the role of low levels of the TP53 mutated clone in the disease origin, before the cytotoxic treatments for the primary malignancy [16]. The gene discussed is TP53; the disease is hematologic disorder.